Related Experiment Videos
Doxazosin in renal impairment.
1Clinical Pharmacology Group, Southampton General Hospital, UK.
Journal of Human Hypertension
|October 1, 1990
Summary
Doxazosin pharmacokinetics are similar in patients with normal or impaired renal function, allowing effective use at similar doses. While renal blood flow is preserved, glomerular filtration rate changes are inconsistent, and postural hypotension may occur initially.
Area of Science:
- Pharmacology
- Nephrology
Background:
- Doxazosin is an alpha-1 blocker used for hypertension and benign prostatic hyperplasia.
- Renal function is a critical consideration for drug dosing and patient safety.
Purpose of the Study:
- To evaluate the pharmacokinetics of doxazosin in patients with normal versus impaired renal function.
- To assess the long-term effects of doxazosin on renal hemodynamics.
Main Methods:
- Pharmacokinetic analysis of doxazosin.
- Assessment of renal blood flow and glomerular filtration rates during treatment.
Main Results:
- Doxazosin pharmacokinetics are comparable in patients with normal and impaired renal function.
- Renal blood flow is maintained during long-term doxazosin treatment.
- Glomerular filtration rates showed inconsistent changes, with potential small reductions.
Conclusions:
- Doxazosin can be safely and effectively administered at similar doses to patients regardless of renal function status.
- Long-term doxazosin therapy appears to preserve renal blood flow, but effects on GFR require further investigation.
- Postural hypotension is a potential side effect, particularly after the initial 1 mg dose.